Despite the high prevalence of MDD and the availability of effective treatments, only one-third of patients experience remission.(1) While many patients show improvement with initial therapy, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial demonstrated that it is not to the level of remission or recovery.(2) Augmentation is particularly helpful in managing patients who have had a partial response to their initial treatment. There has been an increased use of atypical antipsychotics as augmentation agents for patients that do not achieve full remission with traditional antidepressants. For those patients requiring augmentation, is the dose of the atypical antipsychotic different, what is the risk-benefit profile for the use of these agents?

In this evidence-based neuroscienceCME TV activity, experts will explore augmentation strategies to aid clinicians in choosing an individualized treatment plan for patients with difficult to treat depression.

Activity Goal

To incorporate the latest evidence-based augmentation treatment strategies to improve outcomes for patients with MDD.

Learning Objectives

At the end of this CE activity, participants should be able to:
Recognize the importance of remission and recovery as treatment goals for MDD.

Identify the need for improved treatments and involving the patient in treatment decisions for MDD.

Evaluate the role of atypical antipsychotics in the treatment of patients with MDD who do not achieve full remission or recovery.

CME Outfitters, LLC, gratefully acknowledges an educational grant from AstraZeneca Pharmaceuticals in support of this CE activity.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Centerâ€™s Commission on Accreditation.

It has been assigned code 6WASUP-PRV-0645. 1.0 contact hours will be awarded upon successful completion.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists. CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education contact hour.

CCMC Credit (Certified Case Managers):
This program has been approved for 1 hour by the Commission for Case Manager Certification (CCMC).

Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). Otherwise, participants should fully complete and return both the credit request form and activity evaluation located within the course guide for this activity. A certificate or statement of credit will be mailed within 4-6 weeks to all who successfully complete these requirements.

Questions about this CE activity? Call us at 877.CME.PROS (877.263.7767).